<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News – Lyomark</title>
	<atom:link href="https://lyomark.com/en/aktuelles/feed/" rel="self" type="application/rss+xml" />
	<link>https://lyomark.com/en</link>
	<description>New products for indications in neonatology, gastroenterology and oncology</description>
	<lastBuildDate>Wed, 27 May 2026 08:27:32 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updateperiod>
	per hour	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://lyomark.com/site/wp-content/uploads/logo.svg</url>
	<title>News – Lyomark</title>
	<link>https://lyomark.com/en</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Change in Management at Lyomark Pharma GmbH and Bendalis GmbH</title>
		<link>https://lyomark.com/en/changes-in-management-at-lyomark-pharma-gmbh-and-bendalis-gmbh-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Mon, 11 Apr 2022 08:33:11 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Neuigkeiten Lyomark]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=3101</guid>

					<description><![CDATA[Oberhaching, April 2022

Dear Sir or Madam,

Today we are informing you about a personnel change at Lyomark Pharma GmbH and Bendalis GmbH. Mr Parvany will be leaving the companies on 31 March 2022. Mr Parvany has been active in both companies since 2012, initially as Head of Sales and Marketing and as Managing Director since 2019. […]]]></description>
		
		
		
			</item>
		<item>
		<title>Change in Management at Lyomark Pharma GmbH and Bendalis GmbH</title>
		<link>https://lyomark.com/en/changes-in-management-at-lyomark-pharma-gmbh-and-bendalis-gmbh/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 21 Sep 2021 14:49:12 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Neuigkeiten Lyomark]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2923</guid>

					<description><![CDATA[Oberhaching, 21 September 2021 Dear Sir or Madam, Today we are informing you about a change in personnel at Lyomark Pharma GmbH and Bendalis GmbH. Mr Malocho will be leaving the companies on 30.09.2021. Mr Malocho has been employed by both companies since 2006, initially as Head of Supply Chain and since 2014 as Managing Director. We would like […]]]></description>
		
		
		
			</item>
		<item>
		<title>Lung surfactant: A potential candidate for influencing inflammatory responses</title>
		<link>https://lyomark.com/en/lung-surfactant-a-potential-candidate-for-influencing-inflammatory-responses/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Wed, 17 Feb 2021 14:31:14 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Natürliches Surfactant]]></category>
		<category><![CDATA[surfactant]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2870</guid>

					<description><![CDATA[The importance of a healthy and well-functioning immune system is perhaps most evident in times of a global pandemic. Pathogenic microorganisms often find their way into our bodies through the lungs, which requires an initial, appropriately developed immune response. As neutrophils are the first immune cells to reach the site of infection, they play an important role in […]]]></description>
		
		
		
			</item>
		<item>
		<title>Surfactant – helpful in the treatment of COVID-associated pneumonia?</title>
		<link>https://lyomark.com/en/surfactant-useful-in-the-treatment-of-covid-associated-pneumonia/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 15 Dec 2020 08:51:19 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Covid-assoziierter Pneumonie]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Natürliches Surfactant]]></category>
		<category><![CDATA[surfactant]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2816</guid>

					<description><![CDATA[SARS-CoV-2 can lead to a severe form of pneumonia which, under certain circumstances, can trigger acute lung failure (ARDS, „Acute Respiratory Distress Syndrome“). This is an „excessive“ inflammatory response: inflammatory cells and fluid build up in the lungs. This mechanically hinders breathing on the one hand and destroys the anti-inflammatory fluid, the body's own protective film („surfactant“), in the alveoli on the other, which […]]]></description>
		
		
		
			</item>
		<item>
		<title>Feasibility study on Neofact® published: The innovative LISA application aid Neofact® is successful.</title>
		<link>https://lyomark.com/en/neofact-feasibility-study-published/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 09 Oct 2020 13:55:38 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[surfactant]]></category>
		<category><![CDATA[wundheilung]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2739</guid>

					<description><![CDATA[In the clinical study conducted at the University Hospital Tübingen, 20 premature infants (gestational age ≥ 26 + 0/7 weeks) were administered the surfactant Alveofact® (45 mg/ml; Lyomark Pharma, Oberhaching, Germany) with the new LISA application aid Neofact®. The aim of Neofact® was to enable a simple and gentle procedure for surfactant administration, which could be done without the use of […]]]></description>
		
		
		
			</item>
		<item>
		<title>Surfactant – the new preparation for promoting wound healing?</title>
		<link>https://lyomark.com/en/lyomark-pharma-alveofact-wound-healing/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 17 Apr 2020 07:27:11 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[surfactant]]></category>
		<category><![CDATA[wundheilung]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2635</guid>

					<description><![CDATA[Skin wound healing disorders are characterised by persistent inflammation, chronic non-healing ulcers or excessive scarring with an ongoing inflammatory response. Surgical removal of diseased tissue, followed by plastic-reconstructive wound closure or long-term treatment with various wound dressings, currently represents the standard therapy. The social impact of aberrant wound healing, in addition to high healthcare costs and economic consequences, manifests itself […]]]></description>
		
		
		
			</item>
		<item>
		<title>NEOFACT® – The innovative application aid for surfactant instillation</title>
		<link>https://lyomark.com/en/neofact-the-innovative-application-aid-for-surfactant-instillation/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 02 Apr 2019 13:46:26 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[lyomark]]></category>
		<category><![CDATA[Neofact]]></category>
		<category><![CDATA[Surfactant Applikation]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2471</guid>

					<description><![CDATA[Lyomark Pharma remains on a growth trajectory and is launching its own application aid for surfactant instillation onto the market with NEOFACT®. NEOFACT® was developed in practice to support surfactant therapy. Thanks to NEOFACT®, surfactant administration can be carried out easily and without a Magill forceps. Find out more about NEOFACT® here.]]></description>
		
		
		
			</item>
		<item>
		<title>Change in management</title>
		<link>https://lyomark.com/en/change-in-management/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Mon, 01 Apr 2019 07:51:49 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[lyomark]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[parvany]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2521</guid>

					<description><![CDATA[Change at the top of Lyomark Pharma GmbH: Christian Parvany (41) will join the company's management board on April 1st. At the same time, Dr. Helmut Wolf is ending his more than 25-year tenure as managing director at Lyomark Pharma. Dr. Wolf will remain with the company as a shareholder and will continue to support our company's development in this capacity. Christian […]]]></description>
		
		
		
			</item>
		<item>
		<title>NeoKay® – Lyomark Pharma's Vitamin K1 Prophylaxis</title>
		<link>https://lyomark.com/en/neokay-vitamin-k1-prophylaxis-by-lyomark-pharma/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Wed, 09 Jan 2019 16:07:52 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[NeoKay®]]></category>
		<category><![CDATA[Vitamin-K1]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2281</guid>

					<description><![CDATA[Lyomark Pharma is expanding its product portfolio with its own Vitamin K1 prophylaxis for the German market: NeoKay® 1 mg soft capsules. Newborns and infants can develop severe bleeding and particularly intracranial haemorrhages due to physiologically low levels of Vitamin K-dependent clotting factors. To prevent these bleeds, phytomenadione (a synthetic Vitamin K1), which is important for blood clotting in the body, is administered prophylactically. Phytomenadione (Vitamin K1) is [...]]]></description>
		
		
		
			</item>
		<item>
		<title>Aerogen Pharma and Lyomark Pharma are entering into a partnership to develop an inhalable surfactant.</title>
		<link>https://lyomark.com/en/aerogen-pharma-and-lyomark-pharma-are-entering-into-a-partnership-to-develop-an-inhalable-surfactant/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Thu, 14 Dec 2017 13:00:12 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=1487</guid>

					<description><![CDATA[We are delighted to inform you that Lyomark Pharma has entered into a partnership with Aerogen Pharma. The aim of this strategic partnership is to develop an inhalable surfactant for the treatment of respiratory distress syndrome (RDS) in premature newborns, based on our product Alveofact®. At the same time, we have initiated clinical studies with the new application form [...]]]></description>
		
		
		
			</item>
	</channel>
</rss>